Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...

To find out more visit ignite.amicusrx.co.uk LONDON--(BUSINESS WIRE)--Amicus Therapeutics UK Limited (Nasdaq: FOLD), a patient-dedicated biotechnology company, today announced the launch of Amicus ...

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

The Supreme Court has appointed an amicus curiae to assist it on a plea of civil service aspirants, seeking direction to the UPSC for disclosure of the answer keys, cut-off marks and marks of the ...

We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against ...

The amicus curiae will assist SC on a plea of civil service aspirants, seeking direction to the UPSC for disclosure of answer keys, marks of candidates. The Supreme Court has appointed an amicus ...